Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma
出版年份 2016 全文链接
标题
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma
作者
关键词
-
出版物
BRITISH JOURNAL OF HAEMATOLOGY
Volume 176, Issue 5, Pages 783-795
出版商
Wiley
发表日期
2016-12-24
DOI
10.1111/bjh.14483
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
- (2016) N. S. Raje et al. CLINICAL CANCER RESEARCH
- Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma
- (2015) A. McBride et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit
- (2015) Simon J. Harrison et al. AMERICAN JOURNAL OF HEMATOLOGY
- Myeloma today: Disease definitions and treatment advances
- (2015) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- An Enhanced Pre- and Postnatal Development Study in Cynomolgus Monkeys with Tabalumab: A Human IgG4 Monoclonal Antibody
- (2015) William J. Breslin et al. BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY
- Ixazomib for the treatment of multiple myeloma
- (2015) Massimo Gentile et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- An update on the use of lenalidomide for the treatment of multiple myeloma
- (2015) Flora Zagouri et al. EXPERT OPINION ON PHARMACOTHERAPY
- Lenalidomide in multiple myeloma
- (2015) Young Kim et al. Expert Review of Anticancer Therapy
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
- (2015) J. G. Berdeja et al. HAEMATOLOGICA
- Targeting B-cell maturation antigen in multiple myeloma
- (2015) Yu-Tzu Tai et al. Immunotherapy
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- The European Medicines Agency Review of Pomalidomide in Combination With Low-Dose Dexamethasone for the Treatment of Adult Patients With Multiple Myeloma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
- (2015) Z. Hanaizi et al. ONCOLOGIST
- Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma
- (2015) Antonio Palumbo et al. Expert Review of Hematology
- Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
- (2015) S K Kumar et al. Blood Cancer Journal
- B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?
- (2015) P J Hengeveld et al. Blood Cancer Journal
- Multiple Myeloma Gets Three New Drugs
- (2015) Cancer Discovery
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
- (2015) J. G. Berdeja et al. HAEMATOLOGICA
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- Current strategies for treatment of relapsed/refractory multiple myeloma
- (2014) Jacob P Laubach et al. Expert Review of Hematology
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- Evaluation of TNF superfamily molecules in multiple myeloma patients: Correlation with biological and clinical features
- (2013) Dorota Lemancewicz et al. LEUKEMIA RESEARCH
- Relationship between Circulating BAFF Serum Levels with Proliferating Markers in Patients with Multiple Myeloma
- (2013) Michael G. Alexandrakis et al. Biomed Research International
- B cell-activating factor: its clinical significance in multiple myeloma patients
- (2012) M. Fragioudaki et al. ANNALS OF HEMATOLOGY
- Phase I Study of Atacicept in Relapsed/Refractory Multiple Myeloma (MM) and Waldenström's Macroglobulinemia
- (2012) Jean-François Rossi Clinical Lymphoma Myeloma & Leukemia
- Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules
- (2012) Marina Bolzoni et al. EXPERIMENTAL HEMATOLOGY
- Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
- (2012) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
- (2011) S. V. Rajkumar et al. BLOOD
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature
- (2008) A. A. Argyriou et al. BLOOD
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now